Drugs / PH009-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06590194 | Sep 2024 → Jun 2026 overdue | non-small cell lung carcinoma | Suzhou Puhe Pharmaceutical Technology Co., LTD | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PH009-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06590194 ↗ |
| Route | Oral | “PH009-1 75mg QD orally administered” NCT06590194 ↗ |